Bulk Manufacturer of Controlled Substances Application: Groff Global, 60653-60654 [2021-23898]
Download as PDF
<![CDATA[
60653
Federal Register / Vol. 86, No. 210 / Wednesday, November 3, 2021 / Notices
Appendix 3; or (ii) by U.S. government
employees and contract personnel
solely for cybersecurity purposes. The
Commission will not otherwise disclose
any confidential business information in
a manner that would reveal the
operations of the firm supplying the
information.
Summaries of Written Submissions:
The Commission intends to publish
summaries of the positions of interested
persons in this report. If you wish to
have a summary of your position
included in an appendix to the report,
please include a summary with your
written submission and mark the
summary as submitted for that purpose.
The summary may not exceed 500
words, should be in MSWord format or
a format that can be easily converted to
MSWord, and should not include any
confidential business information. The
summary will be published as provided
if it meets these requirements and is
germane to the subject matter of the
investigation. In the report the
Commission will identify the name of
the organization furnishing the
summary and will include a link to the
Commission’s Electronic Document
Information System (EDIS) where the
full written submission can be found.
By order of the Commission.
Issued: October 28, 2021.
Lisa Barton,
Secretary to the Commission.
In
accordance with 21 CFR 1301.33(a), this
is notice that on September 23, 2021,
Nanosyn Inc., 3331 Industrial Drive,
Suite B, Santa Rosa, California 95403–
2062, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Oxymorphone .................
Fentanyl ..........................
I
9652
9801
Schedule
II
III
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of the above controlled
substances in bulk form. No other
activities for these drug codes are
authorized for this registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021–23982 Filed 11–2–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[FR Doc. 2021–23913 Filed 11–2–21; 8:45 am]
BILLING CODE 7020–02–P
[Docket No. DEA–920]
DEPARTMENT OF JUSTICE
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
Drug Enforcement Administration
AGENCY:
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
[Docket No. DEA–921]
Bulk Manufacturer of Controlled
Substances Application: Nanosyn Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Nanosyn Inc. has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTAL
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 3, 2022. Such persons
may also file a written request for a
hearing on the application on or before
January 3, 2022.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
VerDate Sep<11>2014
17:01 Nov 02, 2021
Jkt 256001
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Controlled substance
Marihuana Extract .....................
Psilocybin ..................................
Methylphenidate ........................
Levorphanol ..............................
Noroxymorphone ......................
Tapentadol ................................
Drug
code
Schedule
7350
7437
1724
9220
9668
9780
I
I
II
II
II
II
The company plans to import the
listed controlled substances for clinical
trials only. No other activity for these
drug codes is authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021–23897 Filed 11–2–21; 8:45 am]
Fisher Clinical Services, Inc.
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 3, 2021. Such
persons may also file a written request
for a hearing on the application on or
before December 3, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
SUMMARY:
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on August 25, 2021, Fisher
Clinical Services, Inc., 7554 Schantz
Road, Allentown, Pennsylvania 18106–
9032, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–918]
Bulk Manufacturer of Controlled
Substances Application: Groff Global
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Groff Global has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
SUMMARY:
E:\FR\FM\03NON1.SGM
03NON1
60654
Federal Register / Vol. 86, No. 210 / Wednesday, November 3, 2021 / Notices
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 3, 2022. Such persons
may also file a written request for a
hearing on the application on or before
January 3, 2022.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on September 8, 2021,
Groff Global, 2218 South Queen Street,
York, Pennsylvania 17402–4631,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug
code
Schedule
7437
7438
I
I
Psilocybin ..................................
Psilocyn .....................................
The company plans to bulk
manufacture the listed controlled
substances for internal use or for sale to
its customers.
Brian S. Besser,
Acting Assistant Administrator.
The schedule and agenda for the
meeting are as follows:
10:00 a.m. Commissioner’s Welcome
and Review of Agency
Developments
10:30 a.m. Insurance Claims Data in
Medical Care Price Indexes
1:00 p.m. Generating New Data on
Emerging Topics Using the New
QCEW Business Supplement (QBS)
2:30 p.m. Adjusting Industry Measures
of Hours Worked for Labor
Composition
4:00 p.m. Approximate Conclusion
The meeting is open to the public.
Any questions concerning the meeting
should be directed to Sarah Dale,
Bureau of Labor Statistics Technical
Advisory Committee, at BLSTAC@
bls.gov. Individuals planning to attend
the meeting should register at https://
blstac.eventbrite.com. Individuals who
require special accommodations should
contact Ms. Dale at least two days prior
to the meeting date.
Signed at Washington, DC, this 27th day of
October 2021.
Eric Molina,
Acting Chief, Division of Management
Systems, Bureau of Labor Statistics.
[FR Doc. 2021–23894 Filed 11–2–21; 8:45 am]
BILLING CODE 4510–24–P
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[FR Doc. 2021–23898 Filed 11–2–21; 8:45 am]
BILLING CODE P
[Docket No. OSHA–2013–0012]
Modification to the List of Appropriate
NRTL Program Test Standards and the
Scope of Recognition of Several
NRTLs
DEPARTMENT OF LABOR
Bureau of Labor Statistics
khammond on DSKJM1Z7X2PROD with NOTICES
Technical Advisory Committee; Notice
of Meeting and Agenda
The Bureau of Labor Statistics
Technical Advisory Committee will
meet on Friday, November 19, 2021.
This meeting will be held virtually from
10:00 a.m. to 4:00 p.m. EST.
The Committee presents advice and
makes recommendations to the Bureau
of Labor Statistics (BLS) on technical
aspects of data collection and the
formulation of economic measures and
makes recommendations on areas of
research. The BLS presents issues and
then draws on the expertise of
Committee members representing
specialized fields within the academic
disciplines of economics, statistics and
data science, and survey design. The
Federal Advisory Committee Act
requires that agencies publish notice of
an advisory committee meeting in the
Federal Register.
VerDate Sep<11>2014
17:01 Nov 02, 2021
Jkt 256001
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Notice.
AGENCY:
In this notice, OSHA
announces the final decision to: (1) Add
seven new test standards to the
Nationally Recognized Testing
Laboratories (NRTL) Program’s list of
appropriate test standards; (2) delete or
replace several test standards from the
NRTL Program’s list of appropriate test
standards; and (3) update the scope of
recognition of several NRTLs.
DATES: The actions contained in this
notice will become effective on
November 3, 2021.
FOR FURTHER INFORMATION CONTACT:
Information regarding this notice is
available from the following sources:
Press inquiries: Contact Mr. Frank
Meilinger, Director, OSHA Office of
Communications; telephone: (202) 693–
1999; email: meilinger.francis2@dol.gov.
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
General and technical information:
Contact Mr. Kevin Robinson, Director,
Office of Technical Programs and
Coordination Activities, Directorate of
Technical Support and Emergency
Management, Occupational Safety and
Health Administration; telephone: (202)
693–2110 or email: robinson.kevin@
dol.gov. OSHA’s web page includes
information about the NRTL Program
(see https://www.osha.gov/dts/otpca/
nrtl/).
SUPPLEMENTARY INFORMATION:
I. Background
The NRTL Program recognizes
organizations that provide productsafety testing and certification services
to manufacturers. These organizations
perform testing and certification for
purposes of the program, to U.S.
consensus-based product-safety test
standards. The products covered by the
NRTL Program consist of those items for
which OSHA safety standards require
‘‘certification’’ by a NRTL. The
requirements affect electrical products
and 38 other types of products. OSHA
does not develop or issue these test
standards, but generally relies on
standards development organizations
(SDOs), which develop and maintain
the standards using a method that
provides input and consideration of
views of industry groups, experts, users,
consumers, governmental authorities
and others having broad experience in
the safety field involved.
A. Addition of New Test Standards to
the NRTL List of Appropriate Test
Standards
Periodically, OSHA will add new test
standards to the NRTL list of
appropriate test standards following an
evaluation of the test standard
document. To qualify as an appropriate
test standard, the agency evaluates the
document to (1) verify it represents a
product category for which OSHA
requires certification by a NRTL, (2)
verify the document represents an end
product and not a component, and (3)
verify the document defines safety test
specifications (not installation or
operational performance specifications).
OSHA becomes aware of new test
standards through various avenues. For
example, OSHA may become aware of
new test standards by: (1) Monitoring
notifications issued by certain SDOs; (2)
reviewing applications by NRTLs or
applicants seeking recognition to
include a new test standard in their
scope of recognition; and (3) obtaining
notification from manufacturers,
manufacturing organizations,
government agencies, or other parties
that a new test standard may be
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 86, Number 210 (Wednesday, November 3, 2021)]
[Notices]
[Pages 60653-60654]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-23898]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-918]
Bulk Manufacturer of Controlled Substances Application: Groff
Global
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Groff Global has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
[[Page 60654]]
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before January 3, 2022.
Such persons may also file a written request for a hearing on the
application on or before January 3, 2022.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on September 8, 2021, Groff Global, 2218 South Queen
Street, York, Pennsylvania 17402-4631, applied to be registered as a
bulk manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Psilocybin.............................. 7437 I
Psilocyn................................ 7438 I
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for internal use or for sale to its customers.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021-23898 Filed 11-2-21; 8:45 am]
BILLING CODE P
